Traws Pharma, Inc.
TRAWNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TRAW. That does not mean none is planned.
Get an email about TRAW's next catalysts
Track Traws Pharma (TRAW) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 1 past
TRX-100 Phase 2 Est. Readout
Primary completion for TRX-100 trial (NCT07371650) in Influenza
Final Phase 2a results: ratutrelvir showed median time to sustained symptom resolution of 13.5 days vs 14.5 days for PAXLOVID, no viral rebound through Day 28, and fewer treatment-related adverse events (1 of 32 vs 4 of 30). No treatment-related AEs in the 30 PAXLOVID-ineligible subjects. TXM tablet bridging study met objectives; TXM toxicology retesting showed no mutagenic effect up to 500 mg/kg.
SourceMarket Overview
Stock performance and key metrics
rigosertib sodium
Myelodysplastic Syndromes
ON 01910.Na
Myelodysplastic Syndrome
rigosertib
Head and Neck Squamous Cell Carcinoma
Narazaciclib
Endometrioid Endometrial Cancer
TRX-100
Influenza
Oral rigosertib
Myelodysplastic Syndromes
Ratutrelvir (83-0060)
COVID - 19
Ratutrelvir (83-0060) non-randomised
COVID - 19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rigosertib sodium | Phase 3 | Myelodysplastic Syndromes | - | - |
ON 01910.Na | Phase 3 | Myelodysplastic Syndrome | - | - |
rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer | - | - |
TRX-100 | Phase 2 | Influenza | - | - |
Oral rigosertib | Phase 2 | Myelodysplastic Syndromes | - | - |
Ratutrelvir (83-0060) | Phase 2 | COVID - 19 | - | - |
Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 | - | - |
Myelodysplastic Syndromes
2 drugs in this indication
Endometrioid Endometrial Cancer
1 drug in this indication
COVID - 19
1 drug in this indication
Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Myelodysplastic Syndrome
1 drug in this indication
COVID-19 (mild-to-moderate)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Traws Pharma, Inc.'s drug pipeline?β
CatalystAlert tracks 8 drug candidates in Traws Pharma, Inc.'s (TRAW) pipeline across Phase 3, Phase 2. Its lead program is ON 01910.Na (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Traws Pharma, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Traws Pharma, Inc. (TRAW) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track TRAW biotech catalysts?β
Add TRAW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Traws Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
